Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Galectin-9 is required for endometrial regenerative cells to induce long-term cardiac allograft survival in mice

Fig. 5

Gal-9-ERC-based therapy inhibited CD4+ T and CD8+ T cell response while promoting Treg generation. Immune cells (CD4+ T and CD8+ T) activation and proliferation reflect the severity of acute cellular rejection (ACR). Splenocytes from B6 recipients among each group were harvested on POD8 and then stained for flow cytometry analysis. a Representative dot plots of CD4+ T (CD3+CD4+) and CD8+ T (CD3+CD8+) cells. b Representative dot plots of Treg (CD4+CD25+Foxp3+) cells. c–e Percentage of CD8+ T (CD3+CD8+), CD4+ T (CD3+CD4+) and Treg (CD4+CD25+Foxp3+) cells (n = 6). Differences among groups were assessed by using one-way analysis of variance (ANOVA). *p < 0.05, **p < 0.01. Abbreviations: ERC, endometrial regenerative cell; Gal-9-ERC, Galectin-9 high-expression ERC; POD, postoperative day; Rapa, rapamycin

Back to article page